MedTrace Logo

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

NCT07441785 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-04-22

No results posted yet for this study

Summary

Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues.

Rising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques).

Each method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL.

No consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied.

Systematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.

Conditions

  • Gastric Cancer (GC)
  • Siewert Type III Adenocarcinoma of Esophagogastric Junction
  • Siewert Type II Adenocarcinoma of Esophagogastric Junction

Interventions

PROCEDURE

Proximal Gastrectomy

Resection of the upper third to one-half of the stomach and the distal portion of the esophagus with different types of digestive system reconstruction

Sponsors & Collaborators

  • A.Loginov Moscow Clinical Scientific Center

    collaborator UNKNOWN

  • P. Herzen Moscow Oncology Research Institute

    lead OTHER_GOV

Principal Investigators

  • Andrey Ryabov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Vladimir Khomyakov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Nuriddin Abdulkhakimov, PhD · P.Herzen Moscow Oncological Research Institute

  • Pavel Smirnov · P.Herzen Moscow Oncological Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2028-12-31
Completion
2029-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441785 on ClinicalTrials.gov